Dr. Reddy's Laboratories filed its Annual Report in Form 20-F for the fiscal year ended March 31, 2026, with the United States Securities and Exchange Commission on May 30, 2026. The filing includes annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board (IASB).

The submission was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company disclosed that the report is accessible on its official website for stakeholders.

Filing Details

The intimation was addressed to the National Stock Exchange of India Ltd., BSE Limited, New York Stock Exchange Inc., and NSE IFSC Ltd. K Randhir Singh, Company Secretary, Compliance Officer & Head-CSR, signed the disclosure on behalf of Dr. Reddy's Laboratories Limited.

Dr. Reddy's Laboratories rang the Closing Bell at the New York Stock Exchange (NYSE) on May 29, 2026, to celebrate 25 years of its listing. The company became the first pharmaceutical firm in Asia, outside Japan, to be listed on the NYSE in April 2001. This milestone highlights the company's long-standing presence in the global market and its commitment to governance and transparency.

The ceremony took place at the NYSE headquarters in New York City at 4.00 pm EDT (1.30 am IST on May 30). It was livestreamed on NYSE.com and the New York Stock Exchange YouTube channel. The event marks a significant achievement for the company, reinforcing its position as a trusted name in the U.S. market.

The senior management team, led by Chairman Satish Reddy, participated in the ceremony. Key attendees included Erez Israeli, Chief Executive Officer; M.V. Ramana, Chief Executive Officer-Global Generics; and M.V. Narasimham, Chief Financial Officer. Independent Directors Arun M. Kumar, Penny Wan, and Sridar Iyengar (former Independent Director) were also present.

Satish Reddy, Chairman, emphasized the significance of this milestone, stating it reaffirms the company's commitment to global governance and innovation. He noted that the vision of founder Dr. K. Anji Reddy to bring affordable medicines to patients worldwide continues to drive the company's operations.

Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, the company offers a portfolio of products and services, including APIs, generics, branded generics, biosimilars, and OTC medicines. Its major therapeutic areas include gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.